Gentian Diagnostics AS (OSL:GENT) Ending Cash Position : kr88.7 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Gentian Diagnostics AS Ending Cash Position?

Gentian Diagnostics AS's Ending Cash Position for the quarter that ended in Mar. 2025 was kr88.7 Mil.

Gentian Diagnostics AS's quarterly Ending Cash Position declined from Sep. 2024 (kr93.8 Mil) to Dec. 2024 (kr84.7 Mil) but then increased from Dec. 2024 (kr84.7 Mil) to Mar. 2025 (kr88.7 Mil).

Gentian Diagnostics AS's annual Ending Cash Position increased from Dec. 2022 (kr81.6 Mil) to Dec. 2023 (kr87.6 Mil) but then declined from Dec. 2023 (kr87.6 Mil) to Dec. 2024 (kr84.7 Mil).

Gentian Diagnostics AS Ending Cash Position Historical Data

The historical data trend for Gentian Diagnostics AS's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gentian Diagnostics AS Ending Cash Position Chart

Gentian Diagnostics AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

157.99

114.94

81.60

87.64

84.74

Gentian Diagnostics AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															85.62	81.02	93.80	84.74	88.74

Gentian Diagnostics AS Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Gentian Diagnostics AS's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	87.643	+	-2.905
	=	84.7

Gentian Diagnostics AS's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	84.738	+	4.004
	=	88.7

Gentian Diagnostics AS Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Gentian Diagnostics AS's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Gentian Diagnostics AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gentian Diagnostics AS (OSL:GENT) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

6FK:Germany

Address

Bjornasveien 5, Moss, NOR, 1596

Website

https://www.gentian.com

Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.